Philippe Gevaert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3175724/publications.pdf

Version: 2024-02-01

184 17,730 65 129
papers citations h-index g-index

189 189 189 8494
all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. Journal of Allergy and Clinical Immunology, 2022, 149, 189-199.	1.5	38
2	Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: AÂrandomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2022, 149, 1309-1317.e12.	1.5	147
3	The Role of IgE in Upper and Lower Airway Disease: More Than Just Allergy!. Clinical Reviews in Allergy and Immunology, 2022, 62, 200-215.	2.9	12
4	Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study. Journal of Allergy and Clinical Immunology, 2022, 149, 957-965.e3.	1.5	58
5	COVIDâ€19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 304-307.	2.7	3
6	Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1086-1095.e5.	2.0	42
7	Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER). Journal of Allergy and Clinical Immunology, 2022, 149, 1675-1682.e3.	1.5	12
8	The roles of eosinophils and interleukinâ€5 in the pathophysiology of chronic rhinosinusitis with nasal polyps. International Forum of Allergy and Rhinology, 2022, 12, 1413-1423.	1.5	41
9	Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 732-741.	2.0	16
10	Reboot surgery for chronic rhinosinusitis with nasal polyposis: recurrence and smell kinetics. European Archives of Oto-Rhino-Laryngology, 2022, 279, 5691-5699.	0.8	18
11	Surgery in Nasal Polyp Patients: Outcome After a Minimum Observation of 10 Years. American Journal of Rhinology and Allergy, 2021, 35, 449-457.	1.0	30
12	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	2.7	46
13	Management of patients with chronic rhinosinusitis during the COVIDâ€19 pandemic—An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 677-688.	2.7	33
14	EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. Journal of Allergy and Clinical Immunology, 2021, 147, 29-36.	1.5	178
15	Reply. Journal of Allergy and Clinical Immunology, 2021, 147, 413-414.	1.5	2
16	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	2.7	38
17	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2337-2353.	2.7	78
18	Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP. Rhinology, 2021, 59, 0-0.	0.7	20

#	Article	IF	Citations
19	Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Annals of Allergy, Asthma and Immunology, 2021, 126, 584-592.e1.	0.5	59
20	Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2461-2471.e5.	2.0	50
21	Allergic Rhinitis in Childhood and the New EUFOREA Algorithm. Frontiers in Allergy, 2021, 2, 706589.	1.2	24
22	Mepolizumab for chronic rhinosinusitis with nasal polyps. Lancet Respiratory Medicine, the, 2021, 9, 1081-1082.	5.2	6
23	Pathophysiological and Clinical Aspects of Chronic Rhinosinusitis: Current Concepts. Frontiers in Allergy, 2021, 2, 741788.	1.2	6
24	The role of mobile health technologies in allergy care: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 259-272.	2.7	95
25	Dupilumab improves healthâ&elated quality of life in patients with chronic rhinosinusitis with nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 148-157.	2.7	75
26	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. Clinical and Translational Allergy, 2020, 10, 1.	1.4	110
27	Monoclonal Antibodies and Airway Diseases. International Journal of Molecular Sciences, 2020, 21, 9477.	1.8	10
28	Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma from the Pooled Populations of the SINUS-24 and SINUS-52 Dupilumab Phase 3 Trials., 2020,,.		0
29	Effect of the tongue-in-groove technique on the smile form. Rhinology, 2020, 58, 626-628.	0.7	10
30	Realâ€life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2867-2878.	2.7	45
31	Omalizumab Improves Quality of Life in Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma. Journal of Allergy and Clinical Immunology, 2020, 145, AB250.	1.5	1
32	Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. Journal of Allergy and Clinical Immunology, 2020, 146, 595-605.	1.5	380
33	Omalizumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps Irrespective of Asthma Status. Journal of Allergy and Clinical Immunology, 2020, 145, AB149.	1.5	2
34	Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 1532-1549.e1.	2.0	38
35	Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy. Journal of Allergy and Clinical Immunology, 2020, 146, 1097-1108.	1.5	55
36	Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement. World Allergy Organization Journal, 2020, 13, 100124.	1.6	25

#	Article	IF	CITATIONS
37	COVID-19 and olfactory dysfunction - an ENT perspective to the current COVID-19 pandemic. B-ent, 2020, 16, 81-85.	0.2	23
38	ARIA masterclass 2018: From guidelines to real-life implementation. Rhinology, 2019, 57, 0-0.	0.7	6
39	A prospective, feasibility study to evaluate the efficacy and usability of a novel drivable endoscope in patients with chronic rhinosinusitis. European Archives of Oto-Rhino-Laryngology, 2019, 276, 2499-2505.	0.8	3
40	Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology, 2019, 58, 0-0.	0.7	21
41	Endoscopic Sinus Surgery for Typeâ€2 CRS wNP: An Endotypeâ€Based Retrospective Study. Laryngoscope, 2019, 129, 1286-1292.	1.1	92
42	Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis. Clinical and Translational Allergy, 2019, 9, 30.	1.4	120
43	Prioritizing research challenges and funding for allergy and asthma and the need for translational research—The European Strategic Forum on Allergic Diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2064-2076.	2.7	39
44	A Novel Double-Blind, Placebo-Controlled Food Challenge Matrix for Milk and Raw Egg. International Archives of Allergy and Immunology, 2019, 179, 1-9.	0.9	3
45	Severe spontaneous epistaxis: retrospective study in a tertiary ENT centre. European Archives of Oto-Rhino-Laryngology, 2019, 276, 1693-1699.	0.8	10
46	Stepwise approach towards adoption of allergen immunotherapy for allergic rhinitis and asthma patients in daily practice in Belgium: a BelSACI-Abeforcal-EUFOREA statement. Clinical and Translational Allergy, 2019, 9, 1.	1.4	27
47	D450 OMALIZUMAB EFFICACY AND SAFETY IN NASAL POLYPOSIS: RESULTS FROM TWO PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS. Annals of Allergy, Asthma and Immunology, 2019, 123, S17.	0.5	9
48	P452 DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COMORBID ASTHMA: SINUS-24/SINUS-52 TRIALS. Annals of Allergy, Asthma and Immunology, 2019, 123, S58-S59.	0.5	0
49	Much ado about Biologicals: <i>Highlights of the Master Class on Biologicals, Prague, 2018</i> Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 837-840.	2.7	2
50	EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis. Rhinology, 2019, 57, 162-169.	0.7	32
51	Fcε RI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon allergen immunotherapy. Clinical and Experimental Allergy, 2018, 48, 970-980.	1.4	25
52	Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities. Allergo Journal International, 2018, 27, 56-65.	0.9	54
53	EAACI Position paper on the standardization of nasal allergen challenges. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1597-1608.	2.7	161
54	Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32. Journal of Allergy and Clinical Immunology, 2018, 142, 497-509.e9.	1.5	84

#	Article	IF	CITATIONS
55	Atopic Comorbidities and Biomarkers of Type 2 Inflammation in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Who Failed Intranasal Corticosteroids. Journal of Allergy and Clinical Immunology, 2018, 141, AB90.	1.5	5
56	Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 837-850.	2.7	79
57	Intranasal administration of allergen increases specific IgE whereas intranasal omalizumab does not increase serum IgE levels—A pilot study. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1003-1012.	2.7	19
58	What treatments are effective for common cold in adults and children?. BMJ: British Medical Journal, 2018, 363, k3786.	2.4	20
59	Prospective study on the outcome of the sphenoid drill out procedure. Rhinology, 2018, 56, 178-182.	0.7	9
60	mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology. Rhinology, 2018, 56, 209-215.	0.7	41
61	Development and validation of a standardized double-blind, placebo-controlled food challenge matrix for raw hazelnuts. Clinical and Translational Allergy, 2018, 8, 3.	1.4	5
62	Subtyping of polyposis nasi: phenotypes, endotypes and comorbidities., 2018, 27, 56.		2
63	Reliable mite-specific IgE testing in nasal secretions by means of allergen microarray. Journal of Allergy and Clinical Immunology, 2017, 140, 301-303.e8.	1.5	21
64	Probioticsâ€impregnated bedding covers for house dust mite allergic rhinitis: A pilot randomized clinical trial. Clinical and Experimental Allergy, 2017, 47, 1092-1096.	1.4	10
65	Nonâ€allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1657-1665.	2.7	193
66	Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1512-1516.	2.0	86
67	A possible role of stem cells in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1868-1873.	2.7	14
68	Dupilumab Improves Sense of Smell and Reduces Anosmia Among Patients with Nasal Polyposis and Chronic Sinusitis: Results from a Phase 2a Trial. Journal of Allergy and Clinical Immunology, 2017, 139, AB90.	1.5	5
69	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <scp>EUFOREA</scp> â€ <scp>ARIA</scp> â€ <scp>EPOS</scp> â€ <scp>AIRWAYS ICP</scp> statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305.	2.7	130
70	Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance. Journal of Allergy and Clinical Immunology, 2017, 140, 1250-1267.	1.5	94
71	Development of an LC-MS/MS method for the detection of traces of peanut allergens in chili pepper. Analytical and Bioanalytical Chemistry, 2017, 409, 5201-5207.	1.9	18
72	IL-21 Is Increased in Nasal Polyposis and after Stimulation with <i>Staphylococcus aureus</i> Enterotoxin B. International Archives of Allergy and Immunology, 2017, 174, 161-169.	0.9	20

#	Article	IF	Citations
73	Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial. Journal of Allergy and Clinical Immunology, 2017, 140, 1024-1031.e14.	1.5	376
74	Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report. Clinical and Translational Allergy, 2017, 7, 17.	1.4	107
75	Alcohol hyperâ€responsiveness in chronic rhinosinusitis with nasal polyps. Clinical and Experimental Allergy, 2017, 47, 245-253.	1.4	20
76	Prospective open-label evaluation of long-term low-dose doxycycline for difficult-to-treat chronic rhinosinusitis with nasal polyps. Rhinology, 2017, 55, 175-180.	0.7	28
77	Prospective open-label evaluation of long-term low-dose doxycycline for difficult-to-treat chronic rhinosinusitis with nasal polyps. Rhinology, 2017, 55, 175-180.	0.7	24
78	The effect of systemic treatments on periostin expression reflects their interference with the eosinophilic inflammation in chronic rhinosinusitis with nasal polyps. Rhinology, 2017, 55, 152-160.	0.7	36
79	EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology, 2017, 55, 202-210.	0.7	36
80	The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study. Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology), 2016, 55, 127-127.	0.0	0
81	The response to nasal allergen provocation with grass pollen is reduced inÂpatients with chronic rhinosinusitis with nasal polyposis and grass sensitization. Clinical and Experimental Allergy, 2016, 46, 555-563.	1.4	9
82	The quest for autoreactive antibodies in nasal polyps. Journal of Allergy and Clinical Immunology, 2016, 138, 893-895.e5.	1.5	20
83	Chronic Rhinosinusitis without Nasal Polyps. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 575-582.	2.0	48
84	Recent pharmacological developments in the treatment of perennial and persistent allergic rhinitis. Expert Opinion on Pharmacotherapy, 2016, 17, 657-669.	0.9	14
85	Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis. JAMA - Journal of the American Medical Association, 2016, 315, 469.	3.8	628
86	Allergic Sensitization, High Local IL-5 and IgE Predict Surgical Outcome 12 Years after Endoscopic Sinus Surgery for Chronic Rhinosinusitis with Nasal Polyposis. Journal of Allergy and Clinical Immunology, 2015, 135, AB238.	1.5	14
87	<i>In vivo</i> diagnosis of allergic diseases-allergen provocation tests. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 355-365.	2.7	81
88	Comparison of different medical treatment options for CRSwNP: doxycycline, methylprednisolone, mepolizumab and omalizumab. Clinical and Translational Allergy, 2015, 5, P41.	1.4	1
89	Local Immunoglobulin E in the Nasal Mucosa: Clinical Implications. Allergy, Asthma and Immunology Research, 2015, 7, 321.	1.1	83
90	Nasal Immunity, Rhinitis, and Rhinosinusitis., 2015, , 1899-1921.		1

#	Article	IF	Citations
91	Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. Journal of Allergy and Clinical Immunology, 2015, 136, 1431-1440.	1.5	254
92	Local IgE in nonâ€allergic rhinitis. Clinical and Experimental Allergy, 2015, 45, 872-881.	1.4	79
93	Raised immunoglobulin A and circulating T follicular helper cells are linked to the development of food allergy in paediatric liver transplant patients. Clinical and Experimental Allergy, 2015, 45, 1060-1070.	1.4	18
94	Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells. Clinical and Experimental Immunology, 2015, 180, 542-550.	1.1	51
95	Vascular endothelial growth factor receptor 1 expression in nasal polyp tissue. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 237-245.	2.7	14
96	Dissemination and Implementation of the ARIA Guidelines for Allergic Rhinitis in General Practice. International Archives of Allergy and Immunology, 2014, 163, 106-113.	0.9	15
97	Self-Medication in Persistent Rhinitis: Overuse of Decongestants in Half of the Patients. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 313-319.	2.0	32
98	The Importance of Local Eosinophilia in the Surgical Outcome of Chronic Rhinosinusitis: A 3-Year Prospective Observational Study. American Journal of Rhinology and Allergy, 2014, 28, 260-264.	1.0	154
99	Differences in Initial Immunoprofiles between Recurrent and Nonrecurrent Chronic Rhinosinusitis with Nasal Polyps. American Journal of Rhinology and Allergy, 2014, 28, 192-198.	1.0	170
100	Mixed T Helper Cell Signatures In Chronic Rhinosinusitis with and without Polyps. PLoS ONE, 2014, 9, e97581.	1.1	123
101	Rhinosinusitis and Nasal Polyps. , 2014, , 686-699.		0
102	Nasal allergen provocation test in nasal polyposis with and without allergy. Clinical and Translational Allergy, 2013, 3, O14.	1.4	4
103	Post-transplant food allergy in children is associated with liver and not with renal transplantation: A monocentric comparative study. European Journal of Pediatrics, 2013, 172, 1069-1075.	1.3	37
104	Local Nasal Inflammation: T Cells and B Cells. , 2013, , 47-67.		1
105	Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. Journal of Allergy and Clinical Immunology, 2013, 131, 110-116.e1.	1.5	592
106	Reply. Journal of Allergy and Clinical Immunology, 2013, 132, 247-248.	1.5	1
107	Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today?. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1-7.	2.7	169
108	Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 55-63.	2.7	125

#	Article	IF	Citations
109	Prevalence of Allergic Sensitization versus Allergic Rhinitis Symptoms in an Unselected Population. International Archives of Allergy and Immunology, 2013, 160, 200-207.	0.9	96
110	Inflammation and remodelling patterns in early stage chronic rhinosinusitis. Clinical and Experimental Allergy, 2012, 42, 883-890.	1.4	58
111	The who, where, and when of IgE in allergic airway disease. Journal of Allergy and Clinical Immunology, 2012, 129, 635-645.	1.5	165
112	Omalizumab Is Effective In Allergic And Non-allergic Patients With Nasal Polyps And Asthma. Journal of Allergy and Clinical Immunology, 2012, 129, AB69.	1.5	8
113	IL-21 is Increased in Nasal Polyposis and after Stimulation with Staphylococus Aureus Enterotoxins. Journal of Allergy and Clinical Immunology, 2012, 129, AB69.	1.5	1
114	Local free light chain expression is increased in chronic rhinosinusitis with nasal polyps. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1165-1172.	2.7	21
115	Chronic rhinosinusitis: From one disease to different phenotypes. Pediatric Allergy and Immunology, 2012, 23, 2-4.	1.1	36
116	Local Inflammation in Chronic Upper Airway Disease. Current Pharmaceutical Design, 2012, 18, 2336-2346.	0.9	25
117	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	0.7	1,086
118	EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology, 2012, 50, 1-12.	0.7	1,665
119	European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology Supplement, 2012, 23, 3 p preceding table of contents, 1-298.	6.0	506
120	Pathogenesis of chronic rhinosinusitis: Inflammation. Journal of Allergy and Clinical Immunology, 2011, 128, 728-732.	1.5	301
121	Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis. Journal of Allergy and Clinical Immunology, 2011, 128, 989-995.e8.	1.5	531
122	Mucosal tissue polyclonal IgE is functional in response to allergen and SEB. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 141-148.	2.7	159
123	Diagnostic tools in Rhinology EAACI position paper. Clinical and Translational Allergy, 2011, 1, 2.	1.4	156
124	Pathophysiology of Chronic Rhinosinusitis. Proceedings of the American Thoracic Society, 2011, 8, 115-120.	3.5	78
125	<i>Staphylococcus aureus</i> enterotoxin B facilitates allergic sensitization in experimental asthma. Clinical and Experimental Allergy, 2010, 40, 1079-1090.	1.4	65
126	Increased serum-soluble interleukin-5 receptor alpha level precedes the development of eczema in children. Pediatric Allergy and Immunology, 2010, 21, 1052-1058.	1.1	11

#	Article	lF	Citations
127	Staphylococcus-aureus-derived Superantigens in Nasal Polyp Disease. , 2010, , 83-94.		1
128	Nasal RAG1- and RAG2-Expressing Cells May Suggest the Nose As A Tertiary Lymphoid Organ. Journal of Allergy and Clinical Immunology, 2010, 125, AB204.	1.5	0
129	Oral steroids and doxycycline: Two different approaches to treat nasal polyps. Journal of Allergy and Clinical Immunology, 2010, 125, 1069-1076.e4.	1.5	322
130	Local complement activation in nasal polyposis. Laryngoscope, 2009, 119, 1753-1758.	1.1	35
131	Chronic rhinosinusitis with and without nasal polyps: What is the difference?. Current Allergy and Asthma Reports, 2009, 9, 213-220.	2.4	83
132	Enhanced release of IgE-dependent early phase mediators from nasal polyp tissue. Journal of Inflammation, 2009, 6, 11.	1.5	19
133	Differential expression of the interleukin 5 receptor α isoforms in blood and tissue eosinophils of nasal polyp patients. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 725-732.	2.7	33
134	Important research questions in allergy and related diseases: 3â€chronic rhinosinusitis and nasal polyposis – a GA ² LEN study. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 520-533.	2.7	102
135	Decreased FOXP3 protein expression in patients with asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1539-1546.	2.7	126
136	Role of Staphylococcus Aureus Enterotoxin B in allergic sensitization. Journal of Allergy and Clinical Immunology, 2009, 123, S69-S69.	1.5	0
137	TGF-Î ² signaling and collagen deposition in chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2009, 124, 253-259.e2.	1.5	186
138	Endoscopic Sinus Surgery for Nasal Polyposis. , 2009, , 593-599.		1
139	Nasal Polyps and Rhinosinusitis. , 2009, , 991-1004.		3
140	Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. Journal of Allergy and Clinical Immunology, 2008, 121, 110-115.	1.5	190
141	Mepolizumab, A Humanised Anti-IL-5 Monoclonal Antibody, As Treatment Of Severe Nasal Polyposis. Journal of Allergy and Clinical Immunology, 2008, 121, 797.	1.5	6
142	T-cell regulation in chronic paranasal sinus disease. Journal of Allergy and Clinical Immunology, 2008, 121, 1435-1441.e3.	1.5	308
143	Treatment of Nasal Polyposis with Oral Methylprednisolone: A Double-Blind, Randomized, Placebo-Controlled Trial withÂEvaluation of Clinical and Biological Activity. Journal of Allergy and Clinical Immunology, 2008, 121, S265-S265.	1.5	0
144	Role of staphylococcal superantigens in upper airway disease. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 34-38.	1.1	203

#	Article	IF	CITATIONS
145	Detection of Enterotoxin DNA in <i>Staphylococcus aureus</i> Strains Obtained from the Middle Meatus in Controls and Nasal Polyp Patients. American Journal of Rhinology & Allergy, 2008, 22, 223-227.	2.3	40
146	Role of Staphylococcal Superantigens in Airway Disease. , 2007, 93, 214-236.		72
147	Remodelling in Nasal Polyposis is Independent of TH-Cell Polarisation. Journal of Allergy and Clinical Immunology, 2007, 119, S141.	1.5	0
148	Staphylococcus Aureus Enterotoxin B Stimulation In Nasal Polyps. Journal of Allergy and Clinical Immunology, 2007, 119, S243.	1.5	1
149	Staphylococcus aureus sensitization and allergic disease in early childhood: Population-based birth cohort study. Journal of Allergy and Clinical Immunology, 2007, 119, 930-936.	1.5	45
150	Local immunoglobulin production in nasal polyposis is modulated by superantigens. Clinical and Experimental Allergy, 2007, 37, 1840-1847.	1.4	151
151	Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis. Clinical Allergy and Immunology, 2007, 20, 163-75.	0.7	31
152	Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps. Journal of Allergy and Clinical Immunology, 2006, 118, 1133-1141.	1.5	393
153	Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1280-1289.	2.7	683
154	Aggravation of bronchial eosinophilia in mice by nasal and bronchial exposure to Staphylococcus aureus enterotoxin B. Clinical and Experimental Allergy, 2006, 36, 1063-1071.	1.4	64
155	Organization of secondary lymphoid tissue and local IgE formation toStaphylococcus aureusenterotoxins in nasal polyp tissue. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 71-79.	2.7	198
156	Nasal polyps in patients with and without cystic fibrosis: a differentiation by innate markers and inflammatory mediators. Clinical and Experimental Allergy, 2005, 35, 467-472.	1.4	78
157	Pharmacological Management of Nasal Polyposis. Drugs, 2005, 65, 1537-1552.	4.9	50
158	Transforming Growth Factor \hat{I}^21 in Nasal Remodeling: Differences between Chronic Rhinosinusitis and Nasal Polyposis. American Journal of Rhinology & Allergy, 2004, 18, 267-272.	2.3	66
159	Soluble Interleukin-5 Receptor Alpha Is Increased in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. International Archives of Allergy and Immunology, 2004, 135, 54-61.	0.9	20
160	Aspirin Sensitivity and IgE Antibodies to <i>Staphylococcus aureus</i> Enterotoxins in Nasal Polyposis: Studies on the Relationship. International Archives of Allergy and Immunology, 2004, 133, 255-260.	0.9	77
161	Macrophage mannose receptor in chronic sinus disease. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 606-612.	2.7	30
162	Collection of nasal secretions for immunological analysis. European Archives of Oto-Rhino-Laryngology, 2004, 261, 242-246.	0.8	66

#	Article	IF	Citations
163	Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunology and Allergy Clinics of North America, 2004, 24, 19-43.	0.7	172
164	Staphylococcus aureus colonization and IgE antibody formation to enterotoxins is increased in nasal polyposis. Journal of Allergy and Clinical Immunology, 2004, 114, 981-983.	1.5	386
165	Increased IgE-antibodies to Staphylococcus aureus enterotoxins in patients with COPD. Respiratory Medicine, 2004, 98, 858-864.	1.3	40
166	Transforming growth factor beta1 in nasal remodeling: differences between chronic rhinosinusitis and nasal polyposis. American Journal of Rhinology & Allergy, 2004, 18, 267-72.	2.3	19
167	Superantigens and nasal polyps. Current Allergy and Asthma Reports, 2003, 3, 523-531.	2.4	86
168	Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 371-379.	2.7	96
169	Human beta-defensins and toll-like receptors in the upper airway. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 748-753.	2.7	125
170	Quantitative real time polymerase chain reaction for measurement of human interleukin-5 receptor alpha spliced isoforms mRNA. BMC Biotechnology, 2003, 3, 17.	1.7	18
171	IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma. Journal of Allergy and Clinical Immunology, 2003, 111, 1131-1132.	1.5	115
172	Hyaluronic acid is not up-regulated in nasal polyps. International Congress Series, 2003, 1240, 475-477.	0.2	0
173	IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma. Journal of Allergy and Clinical Immunology, 2003, 111, 1131-2.	1.5	39
174	Wound Healing of the Nasal and Paranasal Mucosa: A Review. American Journal of Rhinology & Allergy, 2002, 16, 77-84.	2.3	104
175	Staphylococcus aureus superantigens and airway disease. Current Allergy and Asthma Reports, 2002, 2, 252-258.	2.4	75
176	Mediators in nasal polyposis. Current Allergy and Asthma Reports, 2002, 2, 481-487.	2.4	59
177	Secretion of TGF-Î ² l, TGF-Î ² 2, EGF and PDGF into nasal fluid after sinus surgery. European Archives of Oto-Rhino-Laryngology, 2002, 259, 234-238.	0.8	24
178	Staphylococcus aureus enterotoxins: a key in airway disease?. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 480-487.	2.7	95
179	Up-regulation of IL-18 in allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 825-830.	2.7	64
180	Wound healing of the nasal and paranasal mucosa: a review. American Journal of Rhinology & Allergy, 2002, 16, 77-84.	2.3	23

#	Article	IF	CITATIONS
181	Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. Journal of Allergy and Clinical Immunology, 2001, 107, 607-614.	1.5	593
182	Nasal Polyposis: Is There a Link between Eosinophils and IgE?. International Archives of Allergy and Immunology, 2001, 124, 315-317.	0.9	0
183	Nasal Polyposis: From Cytokines to Growth. American Journal of Rhinology & Allergy, 2000, 14, 279-290.	2.3	270
184	222 The role of IL-5 and TGF-betal in eosinophilic inflammation in nasal polyps. Journal of Allergy and Clinical Immunology, 2000, 105, S72.	1.5	2